The American Society of Clinical Oncology (ASCO) begins its 2024 annual meeting at the cavernous and labyrinthine McCormick Place convention center in Chicago Friday, May 31. It’s one of the world’s largest cancer research conferences and can be daunting to follow. More than 400 organizations will participate this year, with about 200 sessions ready to convene. The vast majority of the 5,000 abstracts that cover all aspects of cancer treatment have already been released, and they will be scrutinized by the more than 40,000 attendees from around the world.
Scientists at Hansoh Bio LLC, Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed antibody-drug conjugates (ADCs) comprising HER3 (erbB3)-targeting antibodies linked to a cytotoxic drug through a linker.
Merck Sharp & Dohme LLC has described antibody-drug conjugates (ADCs) comprising antibodies targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) linked to exatecan through a linker reported to be useful for the treatment of cancer.
Scientists at the Institute of Cancer Research have generated a proteolysis targeting chimera (PROTAC) that successfully destroyed RIPK1 in cancer cells.
U.S. Precision Medicine Inc. has announced plans to use artificial intelligence (AI) technology to support work on its small-molecule drug candidate for cancer.
Chengdu Zeling Biomedical Technology Co. Ltd. has identified poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Breast cancer is a heterogenous disease in terms of its prognosis and treatment response. Metabolic reprogramming is a potential therapeutic target because of its repercussion on oncogenesis.
Genesis Therapeutics Inc. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
